【振东制药：孙公司购入的2.5亿元信托产品逾期兑付】振东制药公告，孙公司井冈山盛铭购入的长安宁·旷通公司信托贷款集合资金信托计划产品共计2.5亿元，已到期1.39亿元，尚未收到本金，已累计收到投资收益1626.4万元。公司已与资金实际使用方签署《借款及抵押担保协议》，约定资金实际使用方以其开发的房产提供抵押担保，并已办理完相关抵押登记手续。公司将继续督促各方尽快兑付本金及剩余投资收益，并及时履行信息披露义务。

金融界2025-01-17

振东制药公告，孙公司井冈山盛铭购入的长安宁·旷通公司信托贷款集合资金信托计划产品共计2.5亿元，已到期1.39亿元，尚未收到本金，已累计收到投资收益1626.4万元。公司已与资金实际使用方签署《借款及抵押担保协议》，约定资金实际使用方以其开发的房产提供抵押担保，并已办理完相关抵押登记手续。公司将继续督促各方尽快兑付本金及剩余投资收益，并及时履行信息披露义务。

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2504157741?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-01-17 20:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2504157741","market":"hk","top_or_hot":-1,"title":"【振东制药：孙公司购入的2.5亿元信托产品逾期兑付】振东制药公告，孙公司井冈山盛铭购入的长安宁·旷通公司信托贷款集合资金信托计划产品共计2.5亿元，已到期1.39亿元，尚未收到本金，已累计收到投资收益1626.4万元。公司已与资金实际使用方签署《借款及抵押担保协议》，约定资金实际使用方以其开发的房产提供抵押担保，并已办理完相关抵押登记手续。公司将继续督促各方尽快兑付本金及剩余投资收益，并及时履行信息披露义务。","media":"金融界","content":"<div>\n<p>振东制药公告，孙公司井冈山盛铭购入的长安宁·旷通公司信托贷款集合资金信托计划产品共计2.5亿元，已到期1.39亿元，尚未收到本金，已累计收到投资收益1626.4万元。公司已与资金实际使用方签署《借款及抵押担保协议》，约定资金实际使用方以其开发的房产提供抵押担保，并已办理完相关抵押登记手续。公司将继续督促各方尽快兑付本金及剩余投资收益，并及时履行信息披露义务。</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/01/17205247574538.shtml\">网页链接</a>\n\n</div>\n","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【振东制药：孙公司购入的2.5亿元信托产品逾期兑付】振东制药公告，孙公司井冈山盛铭购入的长安宁·旷通公司信托贷款集合资金信托计划产品共计2.5亿元，已到期1.39亿元，尚未收到本金，已累计收到投资收益1626.4万元。公司已与资金实际使用方签署《借款及抵押担保协议》，约定资金实际使用方以其开发的房产提供抵押担保，并已办理完相关抵押登记手续。公司将继续督促各方尽快兑付本金及剩余投资收益，并及时履行信息披露义务。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【振东制药：孙公司购入的2.5亿元信托产品逾期兑付】振东制药公告，孙公司井冈山盛铭购入的长安宁·旷通公司信托贷款集合资金信托计划产品共计2.5亿元，已到期1.39亿元，尚未收到本金，已累计收到投资收益1626.4万元。公司已与资金实际使用方签署《借款及抵押担保协议》，约定资金实际使用方以其开发的房产提供抵押担保，并已办理完相关抵押登记手续。公司将继续督促各方尽快兑付本金及剩余投资收益，并及时履行信息披露义务。\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-17 20:52 北京时间&nbsp;&nbsp;&nbsp;<a href=https://24h.jrj.com.cn/2025/01/17205247574538.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>振东制药公告，孙公司井冈山盛铭购入的长安宁·旷通公司信托贷款集合资金信托计划产品共计2.5亿元，已到期1.39亿元，尚未收到本金，已累计收到投资收益1626.4万元。公司已与资金实际使用方签署《借款及抵押担保协议》，约定资金实际使用方以其开发的房产提供抵押担保，并已办理完相关抵押登记手续。公司将继续督促各方尽快兑付本金及剩余投资收益，并及时履行信息披露义务。</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/01/17205247574538.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://24h.jrj.com.cn/2025/01/17205247574538.shtml","article_id":"2504157741","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2504157741","pubTimestamp":1737118329,"columns":[],"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"振东制药公告，孙公司井冈山盛铭购入的长安宁·旷通公司信托贷款集合资金信托计划产品共计2.5亿元，已到期1.39亿元，尚未收到本金，已累计收到投资收益1626.4万元。公司已与资金实际使用方签署《借款及抵押担保协议》，约定资金实际使用方以其开发的房产提供抵押担保，并已办理完相关抵押登记手续。公司将继续督促各方尽快兑付本金及剩余投资收益，并及时履行信息披露义务。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300158":"振东制药","BK0239":"医药制造","BK0060":"抗癌","BK0186":"小盘成长"},"translate_title":"[Zhendong Pharmaceutical: Overdue payment of 250 million yuan of trust products purchased by Sun Company] Zhendong Pharmaceutical announced that the trust loan collective fund trust plan products of Chang'ning Kuangtong Company purchased by Sun Company Jinggangshan Shengming totaled 250 million yuan, which has expired 139 million yuan, the principal has not yet been received, and the accumulated investment income has been 16.264 million yuan. The company has signed the Loan and Mortgage Guarantee Agreement with the actual user of the funds, stipulating that the actual user of the funds will pr","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300158":1},"content_text":"振东制药公告，孙公司井冈山盛铭购入的长安宁·旷通公司信托贷款集合资金信托计划产品共计2.5亿元，已到期1.39亿元，尚未收到本金，已累计收到投资收益1626.4万元。公司已与资金实际使用方签署《借款及抵押担保协议》，约定资金实际使用方以其开发的房产提供抵押担保，并已办理完相关抵押登记手续。公司将继续督促各方尽快兑付本金及剩余投资收益，并及时履行信息披露义务。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2504157741","isCrawlerRequest":true}